Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...

Adding chemotherapy and bevacizumab to immunotherapy improves tumor control in a high-risk CRC subset, but this benefit comes ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO ...

Presenting new data in the most mature readout to date, with 60% more patients and reported median and 2-year overall survival. Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to ...

CEO Frank K. Bedu-Addo highlighted progress in the VERSATILE-003 Phase III clinical trial evaluating PDS0101 (Versamune HPV) in HPV16-positive recurrent or metastatic head and neck cancer, emphasizing ...